Evolent Health (EVH) Scheduled to Post Earnings on Thursday

Evolent Health (NYSE:EVH) is scheduled to be announcing its earnings results after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of $0.21 per share for the quarter. Evolent Health has set its FY 2024 guidance at EPS and its Q2 2024 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Thursday, May 9th. The technology company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.04. The company had revenue of $639.65 million for the quarter, compared to analysts’ expectations of $601.60 million. Evolent Health had a positive return on equity of 6.90% and a negative net margin of 5.07%. On average, analysts expect Evolent Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Evolent Health Stock Performance

Shares of NYSE EVH opened at $21.78 on Wednesday. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.57. The stock’s 50-day moving average is $21.32 and its 200 day moving average is $26.85. The stock has a market cap of $2.53 billion, a price-to-earnings ratio of -17.42 and a beta of 1.54. Evolent Health has a 1-year low of $17.98 and a 1-year high of $35.00.

Wall Street Analyst Weigh In

EVH has been the topic of a number of analyst reports. Stephens reaffirmed an “overweight” rating and issued a $42.00 price target on shares of Evolent Health in a research note on Tuesday, July 30th. JMP Securities decreased their price target on Evolent Health from $38.00 to $34.00 and set a “market outperform” rating on the stock in a research note on Friday, May 10th. Canaccord Genuity Group decreased their price target on Evolent Health from $44.00 to $41.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. Finally, Citigroup began coverage on Evolent Health in a research report on Monday, April 22nd. They issued a “buy” rating and a $40.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.